NVP-BEZ235 (Dactolisib) is an oral mTOR/PI3K dual inhibitor [186] and has been shown to suppress tumor cell growth by inducing cell cycle arrest and caspase-dependent apoptosis in eight different human bladder cancer cell lines [167]. The gene discussed is MTOR; the disease is urinary bladder carcinoma.